WallStSmart

Core Scientific, Inc. Common Stock (CORZ)vsSynopsys Inc (SNPS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Synopsys Inc generates 2410% more annual revenue ($8.01B vs $319.02M). SNPS leads profitability with a 13.8% profit margin vs -90.5%. SNPS earns a higher WallStSmart Score of 51/100 (C-).

CORZ

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -2.79

SNPS

Buy

51

out of 100

Grade: C-

Growth: 6.7Profit: 5.0Value: 2.0Quality: 5.5
Piotroski: 1/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CORZ.

SNPSSignificantly Overvalued (-858.5%)

Margin of Safety

-858.5%

Fair Value

$44.68

Current Price

$420.32

$375.64 premium

UndervaluedFair: $44.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CORZ2 strengths · Avg: 10.0/10
EPS GrowthGrowth
61.2%10/10

Earnings expanding 61.2% YoY

Debt/EquityHealth
-0.9410/10

Conservative balance sheet, low leverage

SNPS3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
65.5%10/10

Revenue surging 65.5% year-over-year

Market CapQuality
$82.24B9/10

Large-cap with strong market position

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

CORZ4 concerns · Avg: 2.3/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-16.0%2/10

Revenue declined 16.0%

Free Cash FlowQuality
$-121.74M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-2.792/10

Distress zone — elevated risk

SNPS4 concerns · Avg: 2.5/10
Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
2.812/10

Expensive relative to growth rate

P/E RatioValuation
65.3x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CORZ

The strongest argument for CORZ centers on EPS Growth, Debt/Equity.

Bull Case : SNPS

The strongest argument for SNPS centers on Revenue Growth, Market Cap, Price/Book. Revenue growth of 65.5% demonstrates continued momentum.

Bear Case : CORZ

The primary concerns for CORZ are Return on Equity, Revenue Growth, Free Cash Flow.

Bear Case : SNPS

The primary concerns for SNPS are Return on Equity, Piotroski F-Score, PEG Ratio. A P/E of 65.3x leaves little room for execution misses.

Key Dynamics to Monitor

CORZ profiles as a turnaround stock while SNPS is a growth play — different risk/reward profiles.

CORZ carries more volatility with a beta of 6.90 — expect wider price swings.

SNPS is growing revenue faster at 65.5% — sustainability is the question.

SNPS generates stronger free cash flow (822M), providing more financial flexibility.

Bottom Line

SNPS scores higher overall (51/100 vs 29/100) and 65.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Core Scientific, Inc. Common Stock

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Core Scientific, Inc. provides blockchain and artificial intelligence (AI) infrastructure services in the United States. The company is headquartered in Austin, Texas.

Visit Website →

Synopsys Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Synopsys is an American electronic design automation company that focuses on silicon design and verification, silicon intellectual property and software security and quality. Products include logic synthesis, behavioral synthesis, place and route, static timing analysis, formal verification, hardware description language (SystemC, SystemVerilog/Verilog, VHDL) simulators, and transistor-level circuit simulation.

Visit Website →

Want to dig deeper into these stocks?